22.85
0.97 (4.43%)
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Jade Biosciences, Inc. | Menurun | - |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.88 |
|
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade’s pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 0.04% |
| % Dimiliki oleh Institusi | 33.40% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Remedium Capital Partners, Llc | 31 Dec 2025 | 1,577,750 |
| Versant Venture Management, Llc | 31 Dec 2025 | 1,525,820 |
| Avidity Partners Management Lp | 31 Dec 2025 | 1,400,708 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 24.00 (Wedbush, 5.03%) | Beli |
| Median | 23.50 (2.85%) | |
| Rendah | 23.00 (Guggenheim, 0.66%) | Beli |
| Purata | 23.50 (2.85%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 14.23 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Guggenheim | 11 Mar 2026 | 23.00 (0.66%) | Beli | 14.02 |
| Wedbush | 09 Mar 2026 | 24.00 (5.03%) | Beli | 14.43 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |